CN113134007A - 一种醋酸阿比特龙口服制剂及其制备方法 - Google Patents
一种醋酸阿比特龙口服制剂及其制备方法 Download PDFInfo
- Publication number
- CN113134007A CN113134007A CN202010062268.3A CN202010062268A CN113134007A CN 113134007 A CN113134007 A CN 113134007A CN 202010062268 A CN202010062268 A CN 202010062268A CN 113134007 A CN113134007 A CN 113134007A
- Authority
- CN
- China
- Prior art keywords
- abiraterone acetate
- solid dispersion
- copovidone
- mixing
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title claims abstract description 178
- 229960004103 abiraterone acetate Drugs 0.000 title claims abstract description 178
- 238000002360 preparation method Methods 0.000 title claims abstract description 81
- 239000007962 solid dispersion Substances 0.000 claims abstract description 96
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 41
- 229920001531 copovidone Polymers 0.000 claims abstract description 37
- 229940011871 estrogen Drugs 0.000 claims abstract description 18
- 239000000262 estrogen Substances 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims description 75
- 239000002245 particle Substances 0.000 claims description 34
- 239000002775 capsule Substances 0.000 claims description 31
- 238000009826 distribution Methods 0.000 claims description 30
- 238000001816 cooling Methods 0.000 claims description 27
- 238000010438 heat treatment Methods 0.000 claims description 27
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 238000002844 melting Methods 0.000 claims description 23
- 230000008018 melting Effects 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 17
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 13
- 229960000452 diethylstilbestrol Drugs 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 10
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 9
- 229960005309 estradiol Drugs 0.000 claims description 9
- 229930182833 estradiol Natural products 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 7
- 229960004766 estradiol valerate Drugs 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 6
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 6
- 229960000913 crospovidone Drugs 0.000 claims description 6
- 229960002568 ethinylestradiol Drugs 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229940083542 sodium Drugs 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 229940032147 starch Drugs 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 19
- 235000012438 extruded product Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 23
- 238000011049 filling Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 7
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229960001375 lactose Drugs 0.000 description 6
- 229960001855 mannitol Drugs 0.000 description 6
- 238000007873 sieving Methods 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 229960000853 abiraterone Drugs 0.000 description 4
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 229960001424 quinestrol Drugs 0.000 description 4
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010030247 Oestrogen deficiency Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000009474 hot melt extrusion Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 229940098466 sublingual tablet Drugs 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 235000020927 12-h fasting Nutrition 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003439 Artificial menopause Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 description 1
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- -1 lactose compound Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000002661 non steroidal estrogen Substances 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药制剂技术领域,具体涉及一种醋酸阿比特龙口服制剂及其制备方法,将醋酸阿比特龙、共聚维酮、雌激素混合后加热熔融挤出,将挤出物粉碎,得醋酸阿比特龙固体分散体,将醋酸阿比特龙固体分散体与辅料混合后制备制剂;本发明与现有技术相比,溶出迅速、生物利用度高,制备工艺简单,适合工业化大生产。
Description
技术领域
本发明属于医药技术领域,具体涉及一种醋酸阿比特龙口服制剂及其制备方法。
背景技术
醋酸阿比特龙(Abiraterone acetate)是由美国Centocor Ortho公司开发的一种口服有效的CYP17酶不可逆抑制剂,2011年4月经美国FDA批准上市,临床与泼尼松(prednisone)联用治疗去势抵抗性前列腺癌(castration resistant prostatecancer,CRPC)。本品为睾酮合成中关键酶17α-羟化酶-C17,20-裂解酶(人细胞色素P45017酶)的选择性口服抑制剂,能够降低肿瘤标志物前列腺特异性抗原(PSA)的水平,可用于那些已采用药物治疗或经手术切除而肿瘤继续增长的前列腺癌患者。醋酸阿比特龙化学名为3β-乙酰氧基-17-(3-吡啶基)-雄甾-5,16-二烯,分子式C26H33NO2,分子量391.55,化学结构为:
醋酸阿比特龙为白色或类白色非引湿性的结晶性粉末,油水分配系数为5.12(logP),几乎不溶于水。
由于醋酸阿比特龙的水溶性极差,现有制剂检测溶出度均需加入表面活性剂进行。提高活性成分在制剂中的溶出度是困扰本技术领域人员的难题。醋酸阿比特龙生物利用度仅为0.4%,目前国内外上市的醋酸阿比特龙制剂规格为0.25g,每次需服用4片,造成患者服药困难。为了解决药物的难溶、生物利用度低等问题,研究人员可以通过固体分散体等制剂去尝试解决。
专利CN103070828报道了一种醋酸阿比特龙和聚维酮的固体分散体,并将制得的固体分散体微粉化从而大大提高了醋酸阿比特龙的水溶性,有利于醋酸阿比特龙在胃肠道体液中快速溶出,但生物利用度提高不明显。固体分散体制备过程中使用氯仿作为溶剂,在减压干燥的过程中易造成环境污染。
专利CN105267224通过研磨法制备了一种醋酸阿比特龙和无水乳糖的无定形混合物,这种无定形混合物易于粉碎成微粒,用该种微粒制备的固体口服制剂具有更为良好的分散性能和溶出度。该发明制备的制剂在生理环境下溶出度极低,达不到提高生物利用度的效果。
专利CN105616364提供了一种醋酸阿比特龙片及其制备方法,该方法采用甘露醇和微晶纤维素为填充剂,采用原料药与表面活性剂十二烷基硫酸钠共研磨后湿法制粒的方法制备,所制得的醋酸阿比特龙片可压性好,溶出度达到90%以上,稳定性好,片重小,更适合人体口服给药。该发明采用较为常见的工艺制备制剂,该制剂在生理环境下溶出度较差。
专利CN105640906报道一种阿比特龙舌下片及其制备方法,提高对阿比特龙乙酸酯的吸收,降低用药后的不良反应。该制剂作为舌下片却使用大量的十二烷基硫酸钠,口感差,顺应性较差。
专利CN108785256涉及一种固体分散体,该固体分散体含有阿比特龙或其衍生物和载体材料醋酸羟丙甲基纤维素琥珀酸酯,由该固体分散体制而成的制剂具有良好的溶出度、稳定性,可以消除患者之间服药后个体性差异,能够一定程度上消除空腹饱腹给药带来的食物效应等。该发明以肠溶材料醋酸羟丙甲基纤维素琥珀酸酯为载体材料,在生理环境中溶出缓慢,达不到提高生物利用度的目的。
现有技术中,均未能提供一种溶出快、生物利用度高的阿比特龙制剂。
发明内容
鉴于现有技术的缺陷,本发明提供一种在模拟胃液中溶出迅速、生物利用度高的醋酸阿比特龙口服制剂。
针对上述问题,本发明首先采用热熔挤出工艺制备固体分散体,并通过对固体分散体粒度分布来达到提高体外溶出和体内生物利用度的效果。在使用Beagle犬进行生物利用度研究过程中意外发现雌性激素的存在,导致生物利用度的显著提高。根据这一意外发现进行针对性的实验,确定可用的雌激素种类及安全有效的用量范围。其中:①己烯雌酚为人工合成的非甾体类雌激素物质,能产生与天然雌二醇相同的所有药理与治疗作用。主要用于雌激素低下或缺乏症及激素平衡紊乱引起的功能性出血、闭经,还可用于死胎引产前,以提高子宫肌层对催产素的敏感性,以及前列腺癌的故息疗法。配合手术用于前列腺癌:每日6~10mg,3次分服,连用2~3个月。②雌二醇常用于补充女性雌激素不足,亦用以治疗晚期前列腺癌,可使症状明显改善,疼痛减轻。③炔雌醇用于补充雌激素不足,治疗女性性腺功能不良、闭经、更年期综合征等;治疗促性腺激素分泌不足所致性腺功能低下的闭经和不育症、多滤泡卵巢的不育症。④炔雌醚用于围绝经期综合征及产后退奶等,与孕激素合用可作为口服长效避孕药。⑤戊酸雌二醇片适应症为与孕激素联合使用建立人工月经周期中用于补充主要与自然或人工绝经相关的雌激素缺乏。
以上各雌激素类药物,均未见与醋酸阿比特龙联用提高生物利用度的文献报道。
具体而言,本发明的目的是通过以下技术方案得以实现:
一种醋酸阿比特龙固体分散体,所述醋酸阿比特龙固体分散体包含活性成分醋酸阿比特龙、共聚维酮和雌激素。
所述醋酸阿比特龙与共聚维酮、雌激素的重量比为1:0.5~10:0.01~0.1。
优选地,所述醋酸阿比特龙与共聚维酮、雌激素的重量比为1:1~5:0.01~0.08。
在一些实施方案中,所述雌激素选自己烯雌酚、雌二醇、炔雌醇、炔雌醚、戊酸雌二醇中的一种或多种。
本发明还提供了一种包含上述醋酸阿比特龙固体分散体的口服制剂,所述口服制剂包含醋酸阿比特龙固体分散体和药学上可接受的其他辅料。
所述药学上可接受的其他辅料包括填充剂、崩解剂和润滑剂。
在一些实施方案中,所述填充剂为甘露醇、微晶纤维素、乳糖、磷酸氢钙、山梨醇、淀粉、预胶化淀粉、淀粉乳糖复合物中的一种或多种;所述崩解剂为羧甲基淀粉钠、交联羧甲基纤维素钠、交联聚维酮、低取代羟丙基纤维素中的一种或多种;所述润滑剂为硬脂酸镁、硅酸铝镁、硬脂酸富马酸钠中的一种或多种。
在一些实施方案中,所述口服制剂为片剂、胶囊剂。
在一些实施方案中,所述片剂包含醋酸阿比特龙固体分散体、填充剂、崩解剂和润滑剂;所述胶囊剂包含醋酸阿比特龙固体分散体和润滑剂。
所述填充剂、崩解剂和润滑剂的量为药学上可接受的量。
同时,本发明还提供了一种包含所述醋酸阿比特龙固体分散体的口服制剂的制备方法,包括以下步骤:
(1)将醋酸阿比特龙、共聚维酮、雌激素混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与药学上可接受的其他辅料混合,加工成片剂或胶囊剂。
与现有技术相比,具有如下优势:
(1)采用热熔挤出工艺制备,制备工艺简单,可连续生产,避免使用有机溶剂,利于环境保护;
(2)较好的提高了制剂的溶出度,且存储过程中不存在固体分散体老化问题,保证了制剂溶出的稳定性;
(3)生物利用度有明显的提高且个体差异较小,服用剂量明显减小,方便患者服用。
具体实施方式
下面通过实施例来进一步说明本发明。应该正确理解的是:本发明的实施例仅仅是用于说明本发明而给出,而不是对本发明的限制,所以,在本发明的方法前提下对本发明的简单改进均属本发明要求保护的范围。
实施例1醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、雌二醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硬脂酸镁混合均匀,充填胶囊,即得。
实施例2醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、己烯雌酚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硅酸铝镁混合均匀,充填胶囊,即得。
实施例3醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、炔雌醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硬脂酸镁混合均匀,充填胶囊,即得。
实施例4醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、己烯雌酚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硅酸铝镁混合均匀,充填胶囊,即得。
实施例5醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、己烯雌酚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硬脂酸富马酸钠混合均匀,充填胶囊,即得。
实施例6醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、炔雌醚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硬脂酸富马酸钠混合均匀,充填胶囊,即得。
实施例7醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、戊酸雌二醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硬脂酸富马酸钠混合均匀,充填胶囊,即得。
实施例8醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、雌二醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硬脂酸镁混合均匀,充填胶囊,即得。
实施例9醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、雌二醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硅酸铝镁混合均匀,充填胶囊,即得。
实施例10醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、戊酸雌二醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硅酸铝镁混合均匀,充填胶囊,即得。
实施例11醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、雌二醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硬脂酸镁混合均匀,充填胶囊,即得。
实施例12醋酸阿比特龙胶囊
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、己烯雌酚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90为110μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硅酸铝镁混合均匀,充填胶囊,即得。
实施例13醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、炔雌醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与甘露醇、羧甲基淀粉钠混合,然后加入硬脂酸镁混合均匀,压片而成。
实施例14醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、己烯雌酚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与微晶纤维素、交联羧甲基纤维素钠混合,然后加入硅酸铝镁混合均匀,压片而成。
实施例15醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、己烯雌酚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与乳糖、交联聚维酮混合,然后加入硬脂酸富马酸钠混合均匀,压片而成。
实施例16醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、炔雌醚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与磷酸氢钙、低取代羟丙基纤维素混合,然后加入硬脂酸富马酸钠混合均匀,压片而成。
实施例17醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、戊酸雌二醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90为110μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与山梨醇、羧甲基淀粉钠混合,然后加入硬脂酸富马酸钠混合均匀,压片而成。
实施例18醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、雌二醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与淀粉、交联羧甲基纤维素钠混合,然后加入硬脂酸镁混合均匀,压片而成。
实施例19醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、己烯雌酚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与预胶化淀粉、交联聚维酮混合,然后加入硅酸铝镁混合均匀,压片而成。
实施例20醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、炔雌醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与淀粉乳糖复合物、低取代羟丙基纤维素混合,然后加入硬脂酸镁混合均匀,压片而成。
实施例21醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、己烯雌酚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与甘露醇、低取代羟丙基纤维素混合,然后加入硅酸铝镁混合均匀,压片而成。
实施例22醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、己烯雌酚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与乳糖、交联聚维酮混合,然后加入硬脂酸富马酸钠混合均匀,压片而成。
实施例23醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、炔雌醚混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与微晶纤维素、羧甲基淀粉钠混合,然后加入硬脂酸富马酸钠混合均匀,压片而成。
实施例24醋酸阿比特龙片剂
制备工艺:
(1)将醋酸阿比特龙、共聚维酮、戊酸雌二醇混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90为110μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与山梨醇、交联羧甲基纤维素钠混合,然后加入硬脂酸富马酸钠混合均匀,压片而成。
对比实施例1
醋酸阿比特龙 100g
共聚维酮 300g
硅酸铝镁 3g
制备工艺:
(1)将醋酸阿比特龙、共聚维酮混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与硅酸铝镁混合均匀,充填羟丙甲纤维素空心胶囊,即得。
对比实施例2
制备工艺:
将醋酸阿比特龙、共聚维酮、己烯雌酚混合均匀,加无水乙醇制粒,40℃干燥,过20目整粒,与硬脂酸镁混合均匀,充填羟丙甲纤维素空心胶囊,即得。
对比实施例3
制备工艺:
将醋酸阿比特龙和共聚维酮混合均匀,制成物理混合物;双螺杆热熔挤出机的挤出温度设定为100℃,当达到预设温度后启动螺杆,将所得物理混合物加入到挤出机中,经螺杆挤出条状物;将条状物粉碎,过40目筛得到颗粒粒度分布均匀的固体分散体;所得固体分散体与稀释剂、粘合剂、崩解剂、润滑剂按处方中重量混合均匀;压片制成片剂。
对比实施例4
制备工艺:
将醋酸阿比特龙和十二烷基硫酸钠按上述投料量称量混合,研磨过200目漩涡振荡筛;将甘露醇、微晶纤维素、微粉硅胶、交联羧甲基纤维素钠、硬脂酸镁分别过80目漩涡振荡筛;将醋酸阿比特龙、十二烷基硫酸钠、甘露醇、微晶纤维素、交联羧甲基纤维素钠用混合机混匀,混合物后再过80目筛后再次混匀;预混好的原辅料加入高速搅拌制粒机中,加入8%的PVP k29/32粘合剂乙醇水溶液,制得颗粒,过24目筛;制粒结束后,转移至流化床,干燥至颗粒水分≤1.5%;将干燥后的颗粒不锈钢筛网过筛整粒;加入外加辅料后混合均匀,压片。
对比实施例5
1.1固体分散体配比及制备工艺
醋酸阿比特龙 1份
聚维酮K30 1.5份
氯仿 3份
醋酸阿比特龙和聚维酮溶于氯仿中,减压干燥,得固体分散体A。
1.2微粉研磨配比及制备工艺
固体分散体A 1份
水 1份
将固体分散体A分散在水中,进行微粉研磨,研磨时间1h,D(0.9)小于50微米,得混悬液B。
1.3醋酸阿比特龙片制备
制备工艺:(1)处方量称取过100目筛的乳糖、交联聚维酮,混合均匀,备用;
(2)将混悬液B全部加入到(1)中,制粒,干燥,加入硬脂酸镁,压片,即得。
对比实施例6
制备工艺:
将1.0mg的醋酸阿比特龙、100.0mg大豆磷脂、5.0mg胆固醇溶于10ml乙醇中,得溶液A,将溶液A于50℃的水浴中通过旋转蒸发成膜,得膜B;将3mg脂肪酸甘油酯溶于5ml pH=6.8的磷酸盐缓冲液,得溶液C;将溶液C加入膜B中,在5℃以下冷藏40min使膜充分水合,再涡旋混合60min,制得醋酸阿比特龙柔性脂质体。
验证实施例
1、溶出度测定
体外溶出实验,参照中国药典2015年版四部通则0931第一法溶出度测定法,以0.02mol/L磷酸二氢钠缓冲液(用4mol/L NaOH溶液调节pH4.5,含0.1%的十二烷基硫酸钠)900ml为溶出介质,转速为每分种75转,依法操作,分别于10min、20min、30min时,取溶液10ml,滤过,取续滤液,作为供试品溶液。另取醋酸阿比特龙对照品约27.8mg,置10ml量瓶中,加甲醇溶解并稀释至刻度,精密量取1ml,置10ml量瓶中,加溶出介质稀释至刻度,摇匀,作为对照品溶液。照含量测定项下的色谱条件,取供试品溶液和对照品溶液各10μl,注入液相色谱仪,记录色谱图,按外标法以峰面积计算溶出度,结果见表1。
表1醋酸阿比特龙制剂溶出测定结果(%)
由表1可知,本发明所得醋酸阿比特龙口服制剂药物溶出迅速,体外溶出效果好。
2、生物等效性试验
取本发明实施例1-24和对比实施例1-6制备的制剂进行药代动力学实验,每组8只雄性Beagle犬为试验对象,以市售醋酸阿比特龙片(商品名:泽珂@)为参比制剂,进行单剂量、双周期交叉试验。8只雄性Beagle犬分为两组,禁食12h后分别给予实施例制剂和“泽珂@”片(实施例制剂给药剂量为100mg/只,“泽珂@”片给药剂量为250mg/只)。洗脱期10d后交叉试验,用高效液相色谱-串联质谱法测定血浆中阿比特龙浓度,用Win Nonlin 6.4软件按非房室模型计算药代动力学参数,结果见表2。
表2醋酸阿比特龙制剂生物等效性测定结果
注:相对生物利用度F=(AUC实施例制剂*250)/(AUC原研制剂*100)*100%
由表2可知,添加雌激素,极大地提高了制剂的生物利用度,与市售醋酸阿比特龙相比,提高了14倍以上;对比实施例1不含雌激素,与添加雌激素的实施例相比较,生物利用度低;对比实施例2采用普通湿法制粒工艺,溶出度差,进而导致生物利用度差;对比实施例3-6采用现有技术,生物利用度远不及含雌激素实施例,生物利用度差。
Claims (9)
1.一种醋酸阿比特龙固体分散体,其特征在于,所述固体分散体包含活性成分醋酸阿比特龙、共聚维酮和雌激素。
2.根据权利要求1所述的醋酸阿比特龙固体分散体,其特征在于,所述醋酸阿比特龙与共聚维酮、雌激素的重量比为1:0.5~10:0.01~0.1。
3.根据权利要求2所述的醋酸阿比特龙固体分散体,其特征在于,所述醋酸阿比特龙与共聚维酮、雌激素的重量比为1:1~5:0.01~0.08。
4.根据权利要求1所述的醋酸阿比特龙固体分散体,其特征在于,所述雌激素为己烯雌酚、雌二醇、炔雌醇、炔雌醚、戊酸雌二醇中的一种或几种。
5.一种包含权利要求1所述的醋酸阿比特龙固体分散体的口服制剂,其特征在于,所述口服制剂包含醋酸阿比特龙固体分散体和药学上可接受的其他辅料。
6.根据权利要求5所述的口服制剂,其特征在于,所述药学上可接受的其他辅料包括填充剂、崩解剂和润滑剂。
7.根据权利要求6所述的口服制剂,其特征在于,所述填充剂为甘露醇、微晶纤维素、乳糖、磷酸氢钙、山梨醇、淀粉、预胶化淀粉、淀粉乳糖复合物中的一种或多种;所述崩解剂为羧甲基淀粉钠、交联羧甲基纤维素钠、交联聚维酮、低取代羟丙基纤维素中的一种或多种;所述润滑剂为硬脂酸镁、硅酸铝镁、硬脂酸富马酸钠中的一种或几种。
8.根据权利要求5所述的口服制剂,其特征在于,所述口服制剂为片剂、胶囊剂。
9.一种权利要求5~8任一项所述的包含醋酸阿比特龙固体分散体的口服制剂的制备方法,其特征在于,包括以下步骤:
(1)将醋酸阿比特龙、共聚维酮、雌激素混合后加热熔融,挤出条状物,冷却,备用;
(2)将步骤(1)制备条状物粉碎,控制粒度分布D90小于100μm,得醋酸阿比特龙固体分散体;
(3)将步骤(2)制备的醋酸阿比特龙固体分散体与药学上可接受的辅料混合,加工成片剂或胶囊剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010062268.3A CN113134007B (zh) | 2020-01-20 | 2020-01-20 | 一种醋酸阿比特龙口服制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010062268.3A CN113134007B (zh) | 2020-01-20 | 2020-01-20 | 一种醋酸阿比特龙口服制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113134007A true CN113134007A (zh) | 2021-07-20 |
CN113134007B CN113134007B (zh) | 2024-01-30 |
Family
ID=76809109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010062268.3A Active CN113134007B (zh) | 2020-01-20 | 2020-01-20 | 一种醋酸阿比特龙口服制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113134007B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103124563A (zh) * | 2010-08-04 | 2013-05-29 | 佩尔菲丘尔制药有限公司 | 用于前列腺癌治疗的联合治疗 |
US20150133416A1 (en) * | 2012-05-04 | 2015-05-14 | Jagotec Ag | Pharmaceutical Composition Comprising Abiraterone Acetate |
CN109125276A (zh) * | 2017-06-19 | 2019-01-04 | 齐鲁制药有限公司 | 一种醋酸阿比特龙片剂的药物组合物及其制备方法 |
-
2020
- 2020-01-20 CN CN202010062268.3A patent/CN113134007B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103124563A (zh) * | 2010-08-04 | 2013-05-29 | 佩尔菲丘尔制药有限公司 | 用于前列腺癌治疗的联合治疗 |
US20150133416A1 (en) * | 2012-05-04 | 2015-05-14 | Jagotec Ag | Pharmaceutical Composition Comprising Abiraterone Acetate |
CN109125276A (zh) * | 2017-06-19 | 2019-01-04 | 齐鲁制药有限公司 | 一种醋酸阿比特龙片剂的药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113134007B (zh) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6544553B1 (en) | Dosage forms and methods for oral delivery of progesterone | |
CA2470703C (en) | Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation | |
US20060111334A1 (en) | Oral solid dosage forms containing a low dose of estradiol | |
CN104546666A (zh) | 一种非达霉素固体分散体及其制备方法 | |
CN104706640A (zh) | 一种含有厄贝沙坦的药用组合物及其制备工艺 | |
CN103610658A (zh) | 一种免疫调节剂缓释剂及其制备方法 | |
WO2006048261A2 (en) | Oral solid dosage forms containing a low dose of estradiol | |
CN101732235B (zh) | 一种枸橼酸他莫昔芬口服固体制剂的制备方法 | |
CN106309395A (zh) | 一种他克莫司缓释片及其制备方法 | |
CN113134007A (zh) | 一种醋酸阿比特龙口服制剂及其制备方法 | |
CN113546037A (zh) | 一种醋酸阿比特龙栓剂及其制备方法 | |
CN105106149B (zh) | 左炔诺孕酮片及其制法 | |
CN114469879A (zh) | 一种丁溴东莨菪碱微片及其制备方法和制剂 | |
CN112206233A (zh) | 一种依鲁替尼口服制剂及其制备方法 | |
CN114010604B (zh) | 一种帕博西尼固体制剂及其制备方法 | |
CN111214442B (zh) | 一种阿哌沙班共微粉化物 | |
AU2019245827B2 (en) | Pharmaceutical composition comprising brexpiprazole | |
WO2021184611A1 (zh) | 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法 | |
CN114681433A (zh) | 一种醋酸阿比特龙口腔速溶膜剂及其制备方法 | |
CN115364108A (zh) | 一种含cyp抑制剂和递送剂的组合物及其制备方法 | |
CN101623287B (zh) | 一种屈螺酮类似物的治疗更年期综合症的药物组合物 | |
CN113384532A (zh) | 一种cyp17抑制剂固体分散体及其制备方法 | |
CN116236452A (zh) | 一种利托那韦片剂及其制备方法 | |
CN117482055A (zh) | 一种低剂量盐酸决奈达隆片的制备方法 | |
CN116270482A (zh) | 一种阿普米司特药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |